The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy
Official Title: Feasibility of a "Companion for CAR-T" Web App During Chimeric Antigen Receptor T-cell Therapy
Study ID: NCT05362331
Brief Summary: The complex logistics and unique toxicities of chimeric antigen receptor T-cell (CAR-T) therapy require intensive patient education and careful monitoring. The Companion for CAR-T (CC) web app may be able to assist with patient education and preparation, communication between patients and their multidisciplinary teams, and home-based toxicity monitoring.
Detailed Description: This is a single-arm pilot study assessing the feasibility and acceptability of the Companion for CAR-T (CC) web app among patients receiving commercially available CAR-T therapies. Primary Objectives: I. To evaluate the feasibility of the CC web app. II. To evaluate the acceptability of the CC web app to patients. Secondary Objectives: I. To quantify the incidence of fevers being reported via the CC web app. II. To quantify the incidence of electronic Immune Effector Cell-Associated Encephalopathy (eICE) deficits being recorded via the CC web app. Exploratory Objectives: I. To explore patient perceptions regarding the CC web app. II. To explore usage patterns regarding the CC web app. III. To explore trends in patient-reported quality of life (QOL), values, and stressors over time during CAR-T therapy. IV. To explore responses to abnormal findings reported or recorded using the CC web app Participants will be given access to the web application from beginning at the day of study enrollment through Day +100 following CAR-T therapy.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Name: Rahul Banerjee, MD
Affiliation: University of California, San Francisco
Role: PRINCIPAL_INVESTIGATOR